5,6-dimethoxy-2-naphthalenecarboxylic acid | 126674-76-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5,6-dimethoxy-2-naphthalenecarboxylic acid
• 英文别名: 5,6-dimethoxynaphthalene-2-carboxylic acid；5,6-dimethoxy-2-naphthoic acid
• CAS: 126674-76-8
• 化学式: C₁₃H₁₂O₄
• 分子量: 232.236
• InChiKey: RHWBIJFJDHSLFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5,6-dimethoxy-2-naphthalenecarboxylic acid 以100%的产率得到
  参考文献：
  名称：

  Burke (Jr) Terrence R., Lim Benjamin, Marquez Victor E., Li Zhen-Hong, Bo+, J. Med. Chem., 36 (1993) N 4, S 425-432

  摘要：

  DOI：
• 作为产物：
  描述：

  6-bromo-1,2-dihydroxynaphthalene 以86%的产率得到
  参考文献：
  名称：

  Burke (Jr) Terrence R., Lim Benjamin, Marquez Victor E., Li Zhen-Hong, Bo+, J. Med. Chem., 36 (1993) N 4, S 425-432

  摘要：

  DOI：

文献信息

• Arylamide Inhibitors of HIV-1 Integrase
  作者：He Zhao、Nouri Neamati、Abhijit Mazumder、Sanjay Sunder、Yves Pommier、Terrence R. Burke

  DOI：10.1021/jm960449w

  日期：1997.4.1

  Based on data derived from a large number of HIV-1 integrase inhibitors, similar structural features can be observed, which consist of two aryl units separated by a central linker. For many inhibitors fitting this pattern, at least one aryl ring also requires ortho bis-hydroxylation for significant inhibitory potency. The ability of such catechol species to undergo in situ oxidation to reactive quinones

  根据来自大量HIV-1整合酶抑制剂的数据，可以观察到相似的结构特征，该特征由两个被中央连接子分隔的芳基单元组成。对于许多符合这种模式的抑制剂，至少一个芳基环也需要邻双羟基化以显着抑制作用。这类邻苯二酚物质原位氧化成反应性醌的能力对其实用性提出了一种潜在的限制。为了解决这个问题，制备了一系列不含邻双羟基的抑制剂。这些类似物均未显示出明显的抑制作用。因此，采取了另一种方法，其目的是增加效力而不是消除儿茶酚的亚结构。在后面的研究中，萘核被用作芳基成分，因为先前的报告已经表明，相对于基于单环苯基的系统，稠合的双环可能具有更高的亲和力。在单体单元的初步工作中，发现6,7-二羟基-2-萘甲酸（17）（IC50 = 4.7 microM）的效力比其5,6-二羟基异构体19（IC50 = 62.4微米）。特别值得注意的是，游离酸17和其甲酯21的效价之间存在巨大差异（IC50> 200 microM）。由
• Method for the treatment of hyperproliferative epithelial skin diseases
  申请人：The United States of America as represented by the Department of Health

  公开号：US05610185A1

  公开（公告）日：1997-03-11

  The present invention relates to a method of treating hyperproliferative epithelial lesions by topical administration. The method prevents growth and actively cross-links these aberrant cells, thereby killing the cells. The present invention is useful in control and prevention of hyperproliferative epithelial disorders, such as HPV-infected cell lesions, actinic keratosis, melanomas, and malignant and pre-malignant carcinomas.

  本发明涉及一种通过局部给药治疗过度增殖的上皮病变的方法。该方法可以防止细胞的生长并积极地交联这些异常细胞，从而杀死这些细胞。本发明对于控制和预防过度增殖的上皮疾病非常有用，例如HPV感染细胞病变、日光性角化症、黑色素瘤以及恶性和癌前病变的癌症。
• An Alternative Synthesis of the Dopaminergic Drug 2-Amino-1,2,3,4-tetrahydronaphthalene-5,6-diol (5,6-ADTN)
  作者：Süleyman Göksu、Hasan Seçen、Yaşar Sütbeyaz

  DOI：10.1002/hlca.200690030

  日期：2006.2

  Racemic 2-amino-1,2,3,4-tetrahydronaphthalene-5,6-diol (5,6-ADTN; 4) was synthesized from 5,6-dimethoxynaphthalene-2-carboxylic acid (14) in four steps (60% overall yield; Scheme). The crucial steps of the synthesis are Birch reduction of 14 to the valuable synthon 15, Curtius reaction and carbamate formation (16), hydrogenolysis (17), and demethylation to the biologically active hydrobromide salt

  由5,6-二甲氧基萘-2-羧酸（14）分四个步骤（60 ）合成外消旋的2-氨基-1,2,3,4-四氢萘-5,6-二醇（5,6-ADTN; 4）％总产率；方案）。合成的关键步骤是桦木减少14到有价值的合成子15，库尔提斯反应和氨基甲酸酯形成（16），氢解（17），去甲基化和与生物活性氢溴酸盐18的4。
• Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p56lck
  作者：Terrence R. Burke、Benjamin Lim、Victor E. Marquez、Zhen Hong Li、Joseph B. Bolen、Irena Stefanova、Ivan D. Horak

  DOI：10.1021/jm00056a001

  日期：1993.2

  A study was undertaken to prepare inhibitors of the lymphocyte protein-tyrosine kinase p56lck. Using the known p56lck inhibitor 3,4-dihydroxy-alpha-cyanocinnamamide (4) as a lead compound, bicyclic analogues were designed as conformationally constrained mimetics in which the phenyl ring and vinyl side chain of the cinnamamide are locked into a coplanar orientation. Such planarity was rationalized to be an important determinant for binding within a putative flat, cleftlike catalytic cavity. Bicyclic analogues were prepared using the naphthalene, quinoline, isoquinoline, and 2-iminochromene ring systems and examined for their ability to inhibit autophosphorylation of immunopurified p56lck. The most potent analogues were methyl 7,8-dihydroxyisoquinoline-3-carboxylate (12) (IC50 = 0.2 muM) and 7,8-dihydroxyisoquinoline-3-carboxamide (13) (IC50 = 0.5 muM). Inhibition by 12 was not competitive with respect to ATP. These compounds may represent important new structural motifs for the development of p56lck inhibitors.
• Hydroxylated Aromatic Inhibitors of HIV-1 Integrase
  作者：Terrence R. Jr. Burke、Mark Fesen、Abhijit Mazumder、Jessie Yung、Jian Wang、Adelaide M. Carothers、Dezider Grunberger、John Driscoll、Yves Pommier、Kurt Kohn

  DOI：10.1021/jm00021a006

  日期：1995.10

  Efficient replication of HIV-1 requires integration of a DNA copy of the viral genome into a chromosome of the host cell. Integration is catalyzed by the viral integrase, and we have previously reported that phenolic moieties in compounds such as flavones, caffeic acid phenethyl ester (CAFE, 2), and curcumin confer inhibitory activity against HIV-1 integrase. We now extend these findings by performing a comprehensive structure-activity relationship using CAPE analogues. Approximately 30 compounds have been prepared as HIV integrase inhibitors based on the structural lead provided by CAPE, which has previously been shown to exhibit an IC50 value of 7 mu M in our integration assay. These analogues were designed to examine specific features of the parent CAFE structure which may be important for activity. Among the features examined for their effects on inhibitory potency were ring substitution, side chain length and composition, and phenyl ring conformational orientation. In an assay which measured the combined effect of two sequential steps, dinucleotide cleavage and strand transfer, several analogues have IC50 values for 3'-processing and strand transfer lower than those of CAFE. Inhibition of strand transfer was assayed using both blunt-ended and ''precleaved'' DNA substrates. Disintegration using an integrase mutant lacking the N-terminal zinc finger and C-terminal DNA-binding domains was also inhibited by these analogues, suggesting that the binding site for these compounds resides in the central catalytic core. Several CAFE analogues were also tested for selective activity against transformed cells. Taken together, these results suggest that the development of novel antiviral agents for the treatment of acquired immune deficiency syndrome can be based upon inhibition of HIV-1 integrase.